Sifalimumab
Based on 1 Customer Validation
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research.
For research use only. We do not sell to patients.
- Purity : 99.46%
- CAS No.: 1006877-41-3
- Molecular Weight:144.24 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-P99267
RontalizumabIFN-α Antibody -
HY-P99191
EmapalumabIFN-γ Inhibitor -
HY-P99292
FontolizumabAnti-IFN-γ Antibody -
HY-107390A
AX-024 hydrochlorideTCR-Nck Interaction Inhibitor -
HY-P99168
AnifrolumabIFN Receptor Antagonist -
HY-P990036
DazukibartMonoclonal Antibody -
HY-12836A
IFN alpha-IFNAR-IN-1 hydrochlorideIFN alpha-IFNAR Inhibitor -
HY-107390
AX-024TCR Inhibitor -
HY-107390AR
AX-024 hydrochloride (Standard)Reference Standard -
HY-P99032
MonalizumabNKG2A Immune Checkpoint Inhibitor -
HY-112189
Interferon receptor inducer-1IFNAR Agonist -
HY-12836
IFN alpha-IFNAR-IN-1IFN alpha-IFNAR Inhibitor
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
IFNA1
In Vitro
Sifalimumab (3-36 μg/well; 72 h) attenuates lymphocyte cytotoxicity co-cultured with U-87MG[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U-87MG cells and AGS lymphocytes
-
Concentration:3-36 μg/well
-
Incubation Time:72 hours
-
Result:Attenuated lymphocyte cytotoxicity triggered by IFN I (P<0.05).
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wild-type male BALB/c mice[2]
-
Dosage:30 mg/kg and 3 μg/g
-
Administration:Subcutaneous injection; 30 mg/kg and 3 μg/g
-
Result:Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05).
Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration.
Attenuated the CD45 increase (P<0.05).
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized IFN-alpha 1/IFNA13 Protein, Human (HEK293, His, HY-P70241) can bind Sifalimumab. The EC50 for this effect is 1.843 ng/mL.
Chemical Information
-
CAS No. 1006877-41-3
-
Appearance Liquid
-
Molecular Weight 144.24 kDa
-
Color Colorless to light yellow
-
SMILES
[Sifalimumab]
-
Synonyms
MEDI-545; MDX 1103
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13. [Content Brief]
[2]. La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct;8(5):1345-1354. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Sifalimumab Related Classifications
HY-P99219 Related Classifications
Powered by Bioz